There is a number of clinically registered anti-IL6 and anti-IL6R antibodies that could potentially be exploited in this area; however, caution should be exerted with immune therapies until a better understanding of the biology of these tumours and responses to treatment are known. Here, IL6 is linked to neoplasm.